Rabbit B Cell Select Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently peer-reviewed and published in the prestigious journal Autophagy. Titled "Development and Characterization of Phospho-Ubiquitin Antibodies to Monitor PINK1-PRKN Signaling in Cells and Tissue," this study advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like Parkinson's and Alzheimer's.
The study focuses on the development of antibodies that detect damaged mitochondria, which are more common as we age. ImmunoPrecise played a crucial role in this project by applying its proprietary rabbit B Cell Select platform to isolate and generate highly specific antibodies that target phosphorylated ubiquitin (p-S65-Ub), a marker of mitochondrial damage. These antibodies allow researchers to measure mitochondrial health, and the progression of damage related to aging.
Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, commented: "The development of these novel recombinant p-S65-Ub antibodies represents a significant advancement in mitochondrial research. IPA's proprietary high-precision tools not only enhance our understanding of PINK1-PRKN mediated signaling, but also show promising biomarker potential for various clinical applications. We are proud to have contributed to this groundbreaking research, which opens new avenues for studying mitochondrial dysfunction in aging and neurodegenerative diseases, and may lead to improved diagnostic, prognostic, and therapeutic approaches."
IPA is strategically positioned to capitalize on the booming anti-aging market, projected to reach $81.01 billion by 2028 with an 8.2% CAGR. The Company's proprietary B cell Select platform demonstrates its innovative capacity in this high-growth sector. IPA's collaboration with Mayo Clinic showcases its ability to contribute to groundbreaking research in age-related diseases. Simultaneously, IPA maintains a robust internal pipeline through its subsidiary, Talem Therapeutics, focusing on next-generation therapeutic antibodies. This dual approach of supporting external research while developing proprietary assets establishes IPA as a versatile and valuable player in the longevity and aging fields, potentially unlocking significant market opportunities and shareholder value.
ImmunoPrecise's Contributions
ImmunoPrecise Antibodies (IPA) has made a significant contribution to this breakthrough study, showcasing yet another success from their proprietary rabbit B Cell Select platform. The Company's advanced antibody discovery process played a crucial role in the research. Utilizing the B Cell Select platform, IPA isolated specific immune cells from immunized rabbits. These cells were then meticulously screened to identify those producing antibodies highly specific to phosphorylated ubiquitin, a key indicator of mitochondrial damage. From the top-performing cells, IPA generated and validated recombinant antibodies, ensuring optimal sensitivity and accuracy in detecting damaged mitochondria. This achievement further demonstrates the power and versatility of IPA's rabbit B cell platform in producing high-quality, specific antibodies for cutting-edge research applications.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family").
Source: ImmunoPrecise Antibodies Ltd.
兔子 b 細胞選擇平台產生用於研究年齡相關線粒體功能障礙的新抗體
不列顛哥倫比亞省維多利亞--(美國商業資訊)--$IPA #AI--人工智能驅動的生物治療研究和技術公司ImmunoPrecise Antibodies Ltd.(「IPA」 或 「公司」)(納斯達克股票代碼:IPA)宣佈對一項開創性研究做出重大貢獻。這項研究由梅奧診所的頂尖科學家領導,最初發表在bioRxiv上,隨後進行了同行評審並發表在著名期刊《自噬論》上。這項研究題爲 「用於監測細胞和組織中 PINK1-PRKN 信號的磷酸泛素抗體的開發和表徵」,增進了我們對衰老如何影響線粒體健康的理解,線粒體健康是帕金森氏症和阿爾茨海默氏症等神經退行性疾病的關鍵因素。
該研究的重點是開發檢測受損線粒體的抗體,隨着年齡的增長,這種抗體更爲常見。ImmunoPrecise在該項目中發揮了至關重要的作用,它應用其專有的兔子b細胞選擇平台來分離和生成針對磷酸化泛素(p-s65-uB)(線粒體損傷的標誌物)的高特異性抗體。這些抗體使研究人員能夠測量線粒體健康狀況以及與衰老相關的損傷進展。
ImmunoPrecise Antibodies首席執行官詹妮弗·巴斯博士評論說:「這些新型重組p-S65-uB抗體的開發代表着線粒體研究的重大進展。IPA 專有的高精度工具不僅增強了我們對 PINK1-PRKN 介導信號的理解,而且還顯示出生物標誌物在各種臨床應用中的潛力。我們很自豪能夠爲這項開創性的研究做出貢獻,這爲研究衰老和神經退行性疾病中的線粒體功能障礙開闢了新的途徑,並可能改善診斷、預後和治療方法。」
IPA的戰略定位是利用蓬勃發展的抗衰老市場,預計到2028年將達到810.1億美元,複合年增長率爲8.2%。該公司專有的b細胞精選平台展示了其在這個高增長領域的創新能力。IPA與梅奧診所的合作展示了其爲年齡相關疾病的開創性研究做出貢獻的能力。同時,IPA通過其子公司Talem Therapeutics維持了強大的內部產品線,專注於下一代治療性抗體。這種支持外部研究和開發專有資產的雙重方法使IPA成爲長壽和老齡化領域的多功能和有價值的參與者,有可能釋放重要的市場機會和股東價值。
ImmunoPrecise 的貢獻
ImmunoPrecise Antibodies(IPA)爲這項突破性研究做出了重大貢獻,展示了他們專有的兔子b細胞選擇平台的又一成功。該公司先進的抗體發現過程在研究中發揮了至關重要的作用。IPA 利用 b Cell Select 平台,從免疫過的兔子中分離出特定的免疫細胞。然後,對這些細胞進行了仔細篩選,以識別出那些產生對磷酸化泛素高度特異的抗體的細胞,磷酸化泛素是線粒體損傷的關鍵指標。IPA 從表現最好的細胞中生成並驗證了重組抗體,確保了檢測受損線粒體的最佳靈敏度和準確性。這一成就進一步證明了IPA的兔b細胞平台在爲尖端研究應用生產高質量的特異性抗體方面的力量和多功能性。
關於ImmunoPrecise 抗體有限公司
ImmunoPrecise Antibodies Ltd. 是一家生物技術公司,通過一系列專有和專利技術利用多組學建模和複雜的人工智能。該公司擁有一套集成的端到端能力,以支持治療性抗體的開發,並以解決非常複雜的行業挑戰而聞名。IPA在北美和歐洲有幾家子公司,包括Talem Therapeutics LLC、BioStrand BV、ImmunoPrecise Antibodies(加拿大)有限公司和ImmunoPrecise Antibodies(歐洲)有限公司(統稱爲 「IPA家族」)等實體。
來源:ImmunoPrecise 抗體有限公司